Compare Crispr Therapeutics AG (CRSP) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Crispr Therapeutics AG trades at $53.84 (market cap $5.23B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.29. The key difference: Crispr Therapeutics AG is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| CRSP | USIG | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | Fixed Income |
52-Week High | $76.78 | $52.69 |
52-Week Low | $44.34 | $50.18 |
Enterprise Value | $3.65B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
USIG is trading at $50.32, up 0.27% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent corporate actions include dividend payments, with the latest being $0.21 per share. A key development is AM Best's affirmation of credit ratings for USIG subsidiaries following a transaction with Tiptree Inc., as reported by Business Wire on July 30, 2026.
The outlook is cautious due to bearish technical indicators and limited fundamental data availability. Investment opportunities may arise from stable dividend payments and institutional interest, such as Bank of New York Mellon Corp increasing its stake. Risks include reliance on external financial data and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
